Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

Could a new cancer treatment improve your options?

Researchers are exploring a new treatment called PLN-101095 for patients with advanced solid tumors that do not respond to standard immunotherapy. This drug is being tested in a clinical trial known as FORTIFY, which is currently enrolling patients with specific types of cancer, including non-small cell lung cancer and clear cell renal cell carcinoma. The aim is to see if PLN-101095 can enhance the effectiveness of pembrolizumab, a common immunotherapy drug, when given together.

For individuals facing tough cancer battles, this research could be significant. If successful, PLN-101095 may offer a new option for those whose tumors have not responded to existing treatments. The trial is focusing on patients with advanced or metastatic cancers, which can be particularly challenging to treat. The hope is that this combination therapy could improve outcomes and provide a new avenue for recovery.

The FORTIFY trial is in its early stages, specifically a Phase 1b trial, which means researchers are primarily assessing safety and tolerability, along with any signs of effectiveness. While this is an important step in cancer treatment research, it’s essential to understand that the results are still preliminary. Larger trials will be needed to confirm any benefits before this treatment can be widely recommended.

If you’re interested in the latest advancements in cancer treatment, staying informed about ongoing clinical trials like FORTIFY can be beneficial. Engaging with healthcare providers about emerging therapies may provide options for those in need of new treatments.

Source: globenewswire.com